Search

Your search keyword '"Pullarkat, Vinod"' showing total 1,289 results
Start Over Author "Pullarkat, Vinod"
1,289 results on '"Pullarkat, Vinod"'

1. Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

Author

Otoukesh, Salman, Yang, Dongyun, Mokhtari, Sally, Pourhassan, Hoda, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet, Aribi, Ahmed, Artz, Andrew, Aldoss, Ibrahim, Pullarkat, Vinod, Ali, Haris, Blackmon, Amanda, Becker, Pamela, Curtin, Peter, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

2. HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Author

Rainone, Michael, Behrendt, Carolyn E, Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S, Lavasani, Sayeh, Stewart, Daphne B, Yuan, Yuan, Mortimer, Joanne E, Waisman, James R, Patel, Niki, and Pullarkat, Vinod

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Cancer, Precision Medicine, Women's Health, Breast Cancer, 6.1 Pharmaceuticals, Humans, Female, Breast Neoplasms, Retrospective Studies, Receptor, ErbB-2, Maytansine, Trastuzumab, Ado-Trastuzumab Emtansine, Immunoconjugates, Thrombocytopenia, HER2 positive breast cancer, Trastuzumab deruxtecan, Trastuzumab emtansine, Asian ancestry, Receptor, erbB-2, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding.MethodsSubjects in this retrospective cohort were female patients with HER2 positive breast cancer, of Asian or non-Hispanic White ancestry, who initiated T-DM1 or T-DXd from January 2017 through October 2021. Follow-up closed in January 2022. Primary endpoint was dose adjustment for thrombocytopenia. Competing endpoints were discontinuation of drug for other toxicity, disease progression, or for completion of prescribed cycles. The association between Asian ancestry and thrombocytopenia-related dose adjustment was tested at p

Published
2023

3. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Author

Roloff, Gregory W., Aldoss, Ibrahim, Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K., OʼConnor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Ahmed, Naveed, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan C., Mercadal, Santiago, Schwartz, Marc, Tracy, Sean I., Dholaria, Bhagirathbhai, Mukherjee, Akash, Battiwalla, Minoo, Logan, Aaron C., Ladha, Abdullah, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew P., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua P., Solh, Melhem M., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Pullarkat, Vinod, Stock, Wendy, Cassaday, Ryan D., Shah, Bijal D., Faramand, Rawan, Muffly, Lori, Oliai, Caspian, Yaghmour, George, Sutherland, Katherine, Zambrano, Hector, Bradshaw, Danielle, Kubiak, Michal, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Advani, Anjali S., Stefan, Maryann, OʼDwyer, Kristen M., Lee, Catherine J., Blunk, Betsy, and Bishop, Michael R.

Published
2024
Full Text
View/download PDF

4. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

Author

Pollyea, Daniel A, Pratz, Keith W, Wei, Andrew H, Pullarkat, Vinod, Jonas, Brian A, Recher, Christian, Babu, Sunil, Schuh, Andre C, Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, and DiNardo, Courtney D

Subjects
Cancer, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase III as Topic, Clinical Trials, Phase I as Topic, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.Patients and methodsWe analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.ResultsPatients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.ConclusionsIn poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

Published
2022

6. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Author

Desai, Amrita, Samara, Yazeed, Yang, Dongyun, Ball, Brian, Braun, Adam, Koller, Paul, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet, Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Al Malki, Monzr M., Artz, Andrew, Becker, Pamela, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Curtin, Peter, Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

7. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Garciaz, Sylvain, Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

8. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Author

Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Recher, Christian, Schuh, Andre C, Thirman, Michael J, Garcia, Jacqueline S, DiNardo, Courtney D, Vorobyev, Vladimir, Fracchiolla, Nicola S, Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, and Döhner, Hartmut

Subjects
Clinical Research, Prevention, Cancer, Hematology, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Prognosis, Remission Induction, Sulfonamides, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThere is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10-3 in the VIALE-A trial.MethodsThe patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10-3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS.ResultsOne hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10-3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10-3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10-3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10-3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10-3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001).ConclusionPatients who achieved CRc and MRD < 10-3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10-3.

Published
2022

10. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission

Author

Rahman, Zaid Abdel, Othman, Tamer, Saliba, Rima M., Vanegas, Yenny Alejandra Moreno, Mohty, Razan, Ledesma, Celina, Rondon, Gabriela, Jain, Nitin, Jabbour, Elias, Pullarkat, Vinod, Alkhateeb, Hassan B, Kantarjian, Hagop M., Greipp, Patricia T., Nakamura, Ryotaro, Kharfan-Dabaja, Mohamed A., Champlin, Richard E., Forman, Stephen J., Shpall, Elizabeth J., Litzow, Mark R., Foran, James M., Aldoss, Ibrahim, Koller, Paul B., and Kebriaei, Partow

Published
2024
Full Text
View/download PDF

11. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

12. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Zeidan, Amer M, Ando, Kiyoshi, Rauzy, Odile, Turgut, Mehmet, Wang, Ming-Chung, Cairoli, Roberto, Hou, Hsin-An, Kwong, Yok-Lam, Arnan, Montserrat, Meers, Stef, Pullarkat, Vinod, Santini, Valeria, Malek, Kamel, Kiertsman, Flavia, Niolat, Julie, Ramos, Pedro Marques, Menssen, Hans D, Fenaux, Pierre, Miyazaki, Yasushi, and Platzbecker, Uwe

Published
2024
Full Text
View/download PDF

14. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

Author

Agrawal, Vaibhav, Pourhassan, Hoda, Tsai, Ni-Chun, Ngo, Dat, Koller, Paul, Malki, Monzr M. Al, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew, Singh, Dupinder, Becker, Pamela S., Stewart, Forrest M., Smith, Eileen P., Curtin, Peter, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Pullarkat, Vinod, and Aldoss, Ibrahim

Published
2023
Full Text
View/download PDF

18. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Author

Aldoss, Ibrahim, Yang, Dongyun, Tomasian, Vanina, Mokhtari, Sally, Jackson, Ryan, Gu, Zhaohui, Telatar, Milhan, Yew, Hooi, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Mei, Matthew, Arslan, Shukaib, Koller, Paul, Artz, Andrew, Aoun, Patricia, Gu, Dongqing, Snyder, David, Stewart, Forrest M., Curtin, Peter, Stein, Anthony S., Pillai, Raju, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Nakamura, Ryotaro, and Afkhami, Michelle

Published
2022
Full Text
View/download PDF

19. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Author

Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C., Al Malki, Monzr, Aribi, Ahmed, Agrawal, Vaibhav, Sandhu, Karamjeet, Salhotra, Amandeep, Pourhassan, Hoda, Koller, Paul, Ali, Haris, Artz, Andrew, Karras, Nicole, Pawlowska, Anna B., Murphy, Lindsey, Palmer, Joycelynne, Stein, Anthony, Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Forman, Stephen J.

Published
2024
Full Text
View/download PDF

20. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Author

Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., and Nakamura, Ryotaro

Published
2022
Full Text
View/download PDF

22. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

Author

Ustun, Celalettin, Morgan, Elizabeth, Moodie, Erica EM, Pullarkat, Sheeja, Yeung, Cecilia, Broesby‐Olsen, Sigurd, Ohgami, Robert, Kim, Young, Sperr, Wolfgang, Vestergaard, Hanne, Chen, Dong, Kluin, Philip M, Dolan, Michelle, Mrózek, Krzysztof, Czuchlewski, David, Horny, Hans‐Peter, George, Tracy I, Kristensen, Thomas Kielsgaard, Ku, Nam K, Yi, Cecilia Arana, Møller, Michael Boe, Marcucci, Guido, Baughn, Linda, Schiefer, Ana‐Iris, Hilberink, JR, Pullarkat, Vinod, Shanley, Ryan, Kohlschmidt, Jessica, Coulombe, Janie, Salhotra, Amandeep, Soma, Lori, Cho, Christina, Linden, Michael A, Akin, Cem, Gotlib, Jason, Hoermann, Gregor, Hornick, Jason, Nakamura, Ryo, Deeg, Joachim, Bloomfield, Clara D, Weisdorf, Daniel, Litzow, Mark R, Valent, Peter, Huls, Gerwin, Perales, Miguel‐Angel, and Borthakur, Gautam

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Research Initiative, Rare Diseases, Pediatric Cancer, Clinical Research, Childhood Leukemia, Pediatric, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Genetics, Hematology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Core Binding Factors, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Risk Factors, Severity of Illness Index, Translocation, Genetic, Young Adult, acute myeloid leukemia, core-binding factor, disease-free survival, KIT mutation, predictive value, relapse, scoring system, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P

Published
2018

23. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Author

Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H, Sandmaier, Brenda, Horowitz, Mary, Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard, Gale, Robert, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew, Pulsipher, Michael, Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David

Subjects
Acute lymphoblastic leukemia, Allogeneic transplant, Busulfan, Total body irradiation, Administration, Intravenous, Adolescent, Adult, Allografts, Busulfan, Disease-Free Survival, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival Rate, Transplantation Conditioning, Whole-Body Irradiation
Abstract

Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors. With median follow-up of 3.6 years for Bu and 5.3 years for TBI, adjusted 3-year outcomes showed treatment-related mortality Bu 19% versus TBI 25% (P = .04); relapse Bu 37% versus TBI 28% (P = .007); disease-free survival (DFS) Bu 45% versus TBI 48% (P = .35); and overall survival (OS) Bu 57% versus TBI 53% (P = .35). In multivariate analysis, Bu patients had higher risk of relapse (relative risk, 1.46; 95% confidence interval, 1.15 to 1.85; P = .002) compared with TBI patients. Despite the higher relapse, Bu-containing conditioning led to similar OS and DFS following HCT for ALL.

Published
2018

25. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Author

Othman, Tamer, primary, Koller, Paul, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Tinajero, Jose, additional, Ali, Haris, additional, Cai, Ji‐Lian, additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

26. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Author

Othman, Tamer, primary, Li, Shanpeng, additional, Zhang, Jianying, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Chen, Jason, additional, Farol, Leonardo, additional, Sahebi, Firoozeh, additional, Sandhu, Karamjeet, additional, Spielberger, Ricardo, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod, additional, Mei, Matthew, additional, Aldoss, Ibrahim, additional, and Koller, Paul, additional

Published
2024
Full Text
View/download PDF

27. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Robbins, Marjorie, additional, Song, Joo, additional, Al Malki, Monzr M., additional, Otoukesh, Salman, additional, Sandhu, Karamjeet, additional, Agrawal, Vaibhav, additional, Herrera, Alex F., additional, Popplewell, Leslie L., additional, Ghoda, Lucy, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, and Pullarkat, Vinod, additional

Published
2024
Full Text
View/download PDF

28. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer

Author

Pourhassan, Hoda, primary, Zhang, Jianying, additional, Tinajero, Jose, additional, Pullarkat, Vinod, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Al Malki, Monzr, additional, Aribi, Ahmed, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Ali, Haris, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

29. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Author

Peffault de Latour, Régis, primary, Röth, Alexander, additional, Kulasekararaj, Austin G., additional, Han, Bing, additional, Scheinberg, Phillip, additional, Maciejewski, Jaroslaw P., additional, Ueda, Yasutaka, additional, de Castro, Carlos M., additional, Di Bona, Eros, additional, Fu, Rong, additional, Zhang, Li, additional, Griffin, Morag, additional, Langemeijer, Saskia M.C., additional, Panse, Jens, additional, Schrezenmeier, Hubert, additional, Barcellini, Wilma, additional, Mauad, Vitor A.Q., additional, Schafhausen, Philippe, additional, Tavitian, Suzanne, additional, Beggiato, Eloise, additional, Chew, Lee Ping, additional, Gaya, Anna, additional, Huang, Wei-Han, additional, Jang, Jun Ho, additional, Kitawaki, Toshio, additional, Kutlar, Abdullah, additional, Notaro, Rosario, additional, Pullarkat, Vinod, additional, Schubert, Jörg, additional, Terriou, Louis, additional, Uchiyama, Michihiro, additional, Wong Lee Lee, Lily, additional, Yap, Eng-Soo, additional, Sicre de Fontbrune, Flore, additional, Marano, Luana, additional, Alashkar, Ferras, additional, Gandhi, Shreyans, additional, Trikha, Roochi, additional, Yang, Chen, additional, Liu, Hui, additional, Kelly, Richard J., additional, Höchsmann, Britta, additional, Kerloeguen, Cécile, additional, Banerjee, Partha, additional, Levitch, Rafael, additional, Kumar, Rakesh, additional, Wang, Zhixin, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Li, Shujie, additional, Verles, Aurelie, additional, Dahlke, Marion, additional, and Risitano, Antonio M., additional

Published
2024
Full Text
View/download PDF

30. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Author

Mac, Stephanie, Ngo, Dat, Yang, Dongyun, Chen, Jason, Ali, Haris, Arslan, Shukaib, Dadwal, Sanjeet, Salhotra, Amandeep, Cao, Thai, Karras, Nicole, Aldoss, Ibrahim, Koller, Paul, Artz, Andrew, Aribi, Ahmed, Sandhu, Karamjeet, Pullarkat, Vinod, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2021
Full Text
View/download PDF

31. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Author

Han, Se young, Mrózek, Krzysztof, Voutsinas, Jenna, Wu, Qian, Morgan, Elizabeth A., Vestergaard, Hanne, Ohgami, Robert, Kluin, Philip M., Kristensen, Thomas Kielsgaard, Pullarkat, Sheeja, Møller, Michael Boe, Schiefer, Ana-Iris, Baughn, Linda B., Kim, Young, Czuchlewski, David, Hilberink, Jacobien R., Horny, Hans-Peter, George, Tracy I., Dolan, Michelle, Ku, Nam K., Arana Yi, Cecilia, Pullarkat, Vinod, Kohlschmidt, Jessica, Salhotra, Amandeep, Soma, Lori, Bloomfield, Clara D., Chen, Dong, Sperr, Wolfgang R., Marcucci, Guido, Cho, Christina, Akin, Cem, Gotlib, Jason, Broesby-Olsen, Sigurd, Larson, Melissa, Linden, Michael A., Deeg, H. Joachim, Hoermann, Gregor, Perales, Miguel-Angel, Hornick, Jason L., Litzow, Mark R., Nakamura, Ryotaro, Weisdorf, Daniel, Borthakur, Gautam, Huls, Gerwin, Valent, Peter, Ustun, Celalettin, and Yeung, Cecilia C.S.

Published
2021
Full Text
View/download PDF

34. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study.

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron, Stein, Eytan, Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., and Stone, Richard M.

Published
2024
Full Text
View/download PDF

35. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.

Author

Ross, Justine Abella, Lee, Brian, Ma, Huiyan, Tegtmeier, Bernard, Nanayakkara, Deepa, Dickter, Jana, Spielberger, Ricardo, Smith, Eileen, Pullarkat, Vinod, Forman, Stephen J, Taplitz, Randy, Nakamura, Ryotaro, Malki, Monzr Al, and Dadwal, Sanjeet Singh

Subjects
HEMATOPOIETIC stem cell transplantation, ACUTE myeloid leukemia, HOSPITAL admission & discharge, OVERALL survival, UNIVARIATE analysis
Abstract

Background Continuing antifungal prophylaxis (AFPx) to prevent invasive mold infections (IMIs) in recipients of allogeneic hematopoietic cell transplantation (alloHCT) after primary hospital discharge from alloHCT admission varies among transplant centers despite recommendations to continue prophylaxis through day +75. Characteristics driving AFPx prescribing at hospital discharge and outcomes are unknown. Methods In this retrospective analysis, we reviewed patients continuing AFPx vs no AFPx at hospital discharge. We included patients with a hospital stay ≥7 days and ≤40 days. We excluded patients with a history of IMI prior to alloHCT, new IMI during admission, or death prior to discharge. Our primary objective was incidence of probable or proven IMI per the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Our secondary objectives were nonrelapse mortality at day +100, overall survival at day +100, and characteristics driving AFPx discontinuation at hospital discharge. Results Of the 430 patients identified, 387 met inclusion criteria. At discharge, 56% (217/387) continued AFPx, and 44% (170/387) had no AFPx. At day +100, 3 probable IMI cases occurred in the group with continued AFPx vs 1 probable IMI case in the no-AFPx group (no proven IMI). Univariate analysis showed no difference in cumulative incidence of probable IMI (P =.440), nonrelapse mortality (P =.072), and overall survival (P =.855) between groups. Multivariable logistic regression demonstrated that patients were less likely to continue AFPx if they had a diagnosis other than acute myeloid leukemia, a length of stay ≤30 days, acute graft-vs-host disease grade 0 or 1, and corticosteroid use ≤5 days. Conclusions There was no difference in probable IMI at day +100 after alloHCT based on continuing vs discontinuing AFPx at hospital discharge after alloHCT admission supporting a risk-adapted prophylaxis approach. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.

Author

Tinajero, Jose, Ngo, Dat, Zhang, Jianying, Tsai, Ni-Chun, Aribi, Ahmed, Aldoss, Ibrahim, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Pourhassan, Hoda, Sandhu, Karamjeet, Al-Malki, Monzr, Pullarkat, Vinod, Becker, Pamela, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Artz, Andrew, Koller, Paul, and Salhotra, Amandeep

Subjects
ACUTE myeloid leukemia, OLDER patients
Abstract

This document presents data on the outcomes and toxicities of a treatment regimen for older adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The study found that the treatment approach, which included induction chemotherapy with the addition of midostaurin, resulted in a high complete remission rate and a median overall survival of 9.3 months. Additionally, a significant number of patients underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with favorable outcomes. The authors conclude that this treatment approach is feasible and effective for older adults with FLT3-mutated AML. However, the study lacked long-term follow-up and data on minimal residual disease achievement and allo-HCT outcomes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

38. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

Author

Mei, Matthew, Tsai, Ni-Chun, Mokhtari, Sally, Al Malki, Monzr M., Ali, Haris, Salhotra, Amandeep, Sandhu, Karamjeet, Khaled, Samer, Smith, Eileen, Snyder, David, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Stein, Anthony, Aldoss, Ibrahim, and Nakamura, Ryotaro

Published
2020
Full Text
View/download PDF

39. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Salhotra, Amandeep, Yang, Dongyun, Mokhtari, Sally, Malki, Monzr M. Al, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Mei, Matthew, Budde, Elizabeth, Snyder, David, Cao, Thai, Spielberger, Ricardo, Marcucci, Guido, Pullarkat, Vinod, Forman, Stephen J., Nakamura, Ryotaro, Stein, Anthony, and Aldoss, Ibrahim

Published
2020
Full Text
View/download PDF

41. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

Author

Salhotra, Amandeep, Hui, Susanta, Yang, Dongyun, Mokhtari, Sally, Mei, Matthew, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Dandapani, Savita, Peng, Kelly, Teh, Jennifer Berano, Murata-Collins, Joyce, Budde, Elizabeth, Dadwal, Sanjeet, Pullarkat, Vinod, Snyder, David, Spielberger, Ricardo, Wong, Jeffry, Armenian, Saro, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Stein, Anthony

Published
2020
Full Text
View/download PDF

42. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Author

Nakamura, Ryotaro, primary, La Rosa, Corinna, additional, Yang, Dongyun, additional, Hill, Joshua A., additional, Rashidi, Armin, additional, Choe, Hannah, additional, Zhou, Qiao, additional, Lingaraju, Chetan Raj, additional, Kaltcheva, Teodora, additional, Longmate, Jeffrey, additional, Drake, Jennifer, additional, Slape, Cynthia, additional, Duarte, Lupe, additional, Al Malki, Monzr M., additional, Pullarkat, Vinod A., additional, Aribi, Ahmed, additional, Devine, Steven, additional, Verneris, Michael R., additional, Miller, Jeffrey S., additional, Forman, Stephen J., additional, Aldoss, Ibrahim, additional, and Diamond, Don J., additional

Published
2024
Full Text
View/download PDF

43. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

44. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

Author

Samara, Yazeed, primary, Yao, Janny, additional, Tsai, Ni-Chun, additional, Mokhtari, Sally, additional, Aldoss, Ibrahim, additional, Ali, Haris, additional, Sandhu, Karamjeet S., additional, Salhotra, Amandeep, additional, Stein, Anthony S., additional, Arslan, Shukaib, additional, Aribi, Ahmed, additional, Borogovac, Azra, additional, Malki, Monzr M. Al, additional, Blackmon, Amanda, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Curtin, Peter, additional, Pourhassan, Hoda, additional, Koller, Paul, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Spielberger, Ricardo, additional, Becker, Pamela S., additional, Stewart, F. Marc, additional, Smith, Eileen, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

45. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Author

Salhotra, Amandeep, primary, Bejanyan, Nelli, additional, Yang, Dongyun, additional, Mokhtari, Sally, additional, Al Malki, Monzr M., additional, Sandhu, Karamjeet S., additional, Faramand, Rawan G, additional, Aldoss, Ibrahim, additional, Artz, Andrew S., additional, Aribi, Ahmed, additional, Elmariah, Hany, additional, Sahebi, Firoozeh, additional, Mansour, Joshua, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Li, Ling, additional, Pullarkat, Vinod, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Stein, Anthony S., additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

46. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, primary, Lin, Chenyu, additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Faramand, Rawan G, additional, Kopmar, Noam E., additional, Dykes, Kaitlyn C, additional, Jeyakumar, Nikeshan, additional, Dekker, Simone E., additional, Gupta, Vishal, additional, Ahmed, Mohamed, additional, Logan, Aaron C., additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Kubiak, Michal, additional, Mukherjee, Akash, additional, Majhail, Navneet S., additional, Battiwalla, Minoo, additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Shaughnessy, Paul J., additional, Ladha, Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Solh, Melhem M, additional, Lee, Catherine J., additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Tsai, Dr. Stephanie B., additional, and Dholaria, Dr. Bhagirathbhai, additional

Published
2024
Full Text
View/download PDF

47. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib

Author

Ngo, Dat, primary, Tinajero, Jose, additional, Li, Shanpeng, additional, Palmer, Joycelynne, additional, Pourhassan, Hoda, additional, Aribi, Ahmed, additional, Nakamura, Ryotaro, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Pullarkat, Vinod, additional, Ball, Brian, additional, and Koller, Paul, additional

Published
2024
Full Text
View/download PDF

49. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Zeidan, Amer M, primary, Ando, Kiyoshi, additional, Rauzy, Odile, additional, Turgut, Mehmet, additional, Wang, Ming-Chung, additional, Cairoli, Roberto, additional, Hou, Hsin-An, additional, Kwong, Yok-Lam, additional, Arnan, Montserrat, additional, Meers, Stef, additional, Pullarkat, Vinod, additional, Santini, Valeria, additional, Malek, Kamel, additional, Kiertsman, Flavia, additional, Niolat, Julie, additional, Ramos, Pedro Marques, additional, Menssen, Hans D, additional, Fenaux, Pierre, additional, Miyazaki, Yasushi, additional, and Platzbecker, Uwe, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results